NCT00656812 - Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Lymphoma of Mucosa-Associated Lymphoid Tissue

Interventions

DRUG

Rituximab

375 mg/m2 on day 1 of a 21-day treatment cycle

DRUG

2-CdA

0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle

Trial Locations (5)

Universitätsklinikum Graz, Graz

Universitaetsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck

Krankenhaus der Stadt Linz, Linz

Universitaetsklinik f. Innere Medizin III, Salzburg

AKH Wien / Universitaetsklinik fuer Innere Medizin I, Vienna